AbbVie Inc (ABBV)vsHyperfine Inc (HYPR)
ABBV
AbbVie Inc
$206.60
-2.23%
HEALTHCARE · Cap: $360.63B
HYPR
Hyperfine Inc
$1.87
+12.65%
HEALTHCARE · Cap: $163.54M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 450833% more annual revenue ($61.16B vs $13.56M). ABBV leads profitability with a 6.9% profit margin vs -262.3%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
HYPR
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.3%
Fair Value
$163.59
Current Price
$206.60
$43.01 premium
Intrinsic value data unavailable for HYPR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 128.0% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -79.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth. Revenue growth of 128.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while HYPR is a hypergrowth play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.06 — expect wider price swings.
HYPR is growing revenue faster at 128.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 25/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is an innovative leader in medical technology, renowned for developing the first FDA-cleared portable MRI system that revolutionizes access to imaging at the point of care. By delivering high-quality imaging directly at the bedside, Hyperfine enhances patient care and streamlines clinical decision-making, addressing the growing demand for efficient and accessible diagnostic solutions. The company's focus on cost efficiency and patient convenience uniquely positions it within the evolving healthcare landscape, making it a compelling opportunity for institutional investors seeking to invest in transformative healthcare advancements.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?